Creso Pharma Limited
COPHF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $19 | $9 | $6 | $2 |
| % Growth | 117.8% | 39.7% | 154% | – |
| Cost of Goods Sold | $17 | $8 | $7 | $6 |
| Gross Profit | $2 | $0 | -$0 | -$4 |
| % Margin | 12.3% | 3.3% | -6.4% | -158.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5 | $6 | $4 | $3 |
| SG&A Expenses | $6 | $8 | $10 | $4 |
| Sales & Mktg Exp. | $1 | $2 | $6 | $1 |
| Other Operating Expenses | -$4 | $12 | $18 | $6 |
| Operating Expenses | $2 | $19 | $28 | $10 |
| Operating Income | -$17 | -$20 | -$28 | -$17 |
| % Margin | -88.2% | -225.2% | -455.5% | -687.9% |
| Other Income/Exp. Net | -$19 | -$13 | -$2 | -$14 |
| Pre-Tax Income | -$36 | -$33 | -$30 | -$31 |
| Tax Expense | -$0 | $0 | $2 | $7 |
| Net Income | -$52 | -$33 | -$32 | -$38 |
| % Margin | -277.2% | -377.3% | -510.8% | -1,535.2% |
| EPS | 0 | -0.022 | -0.029 | -0.1 |
| % Growth | 100% | 22% | 71.3% | – |
| EPS Diluted | 0 | -0.022 | -0.029 | -0.1 |
| Weighted Avg Shares Out | 0 | 1,463 | 1,107 | 371 |
| Weighted Avg Shares Out Dil | 0 | 1,463 | 1,107 | 371 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $10 | $1 | $2 | $9 |
| Depreciation & Amortization | $1 | $2 | $0 | $0 |
| EBITDA | -$25 | -$18 | -$28 | -$16 |
| % Margin | -133% | -202.8% | -451.2% | -673.5% |